我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

超敏C反应蛋白水平与急性冠脉综合征关系的新进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2010年第2期
页码:
289-292,301
栏目:
综述
出版日期:
2010-03-04

文章信息/Info

Title:
-
作者:
童廉琦1综述; 张荣林2审校
1.南京医科大学鼓楼临床医学院心内科；2.南京大学医学院附属鼓楼医院心内科，江苏 南京 210008
Author(s):
-
关键词:
超敏C反应蛋白; 急性冠脉综合征; 诊断; 预测
Keywords:
-
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
现已明确，轻度慢性炎症在急性冠脉综合征（ACS）的发生、发展中扮演了重要的角色。作为炎症敏感标记物之一的超敏C反应蛋白（hs-CRP），其对于ACS的诊断及预测价值已受到广泛重视，被认为是该病的独立危险因子。已知降低其水平有可能对该病的患者具有潜在的治疗价值，而且对于hs-CRP水平偏高的正常人群，有可能预防首次冠脉事件的发生，但这还需要更多的临床证据证明。
Abstract:
-

参考文献/References

［1］ 殷忠，李兰荪，张荣庆，等. 急性冠脉综合征患者外周血MMP-9及CRP的变化及其临床意义［J］. 心脏杂志， 2006， 18（3）：318-319，322.

［2］ 王文清，宁波，王新宴，等. C反应蛋白与冠心病病变程度的相关性［J］. 心脏杂志， 2006， 18（3）：323-325.

［3］ Potsch AA, Siqueira Filho AG,Tura BR, et al. C-reactive protein diagnostic and prognostic value in patients presenting at the emergency room with chest pain［J］. Arq Bras Cardiol, 2006, 87(3):275-280.

［4］ Ishikawa T, Imamum T, Hatakeyama K, et al. Possible Contribution of C-reactive protein within coronary plaque to Increasing its own plasma levels across coronary circulation［J］. Am J Catdiol, 2004, 93(5):611-614.

［5］ 孙磊，股翔，徐日新，等. 冠心病患者超敏C反应蛋白的变化及临床意义［J］. 实用医学杂志， 2005， 21(17)：1922-1923.

［6］ Hung MJ, Cherng WJ, Yang NI, et al. Relation of high-sensitivity C-reactive protein level with coronary vasospastic angina pectoris in patients without hemodynamically significant coronary artery disease［J］. Am J Cardiol, 2005, 96(11):1484-1490.

［7］ 葛智平，陈晓春. C反应蛋白与不同类型冠心病相关性的临床研究［J］. 临床心血管病杂志， 2005， 21（2）：78-80.

［8］ Brunetti ND, Troccoli R, Correale M, et al. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings［J］. Int J Cardiol, 2006, 109(2):248-256.

［9］ Jahn J, Hellmann I, Maass M, et al. Time-dependent changes of hs-CRP serum concentration in patients with non-ST elevation acute coronary syndrome［J］. Herz, 2004, 29(8):795-801.

［10］Bodí V, Sanchis J, Llàcer A, et al. Independent role of C reactive protein to predict majoy events at one-month and at one-year in acute coronary syndrome without ST elevation［J］. Med Clin (Barc), 2004, 122(7):248-252.

［11］Correia LC, Lima JC, Rocha MS, et al. Does high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-ST elevation acute coronary syndromes?［J］. Clin Chim Acta, 2007, 375(1-2):124-128.

［12］Tello-Montoliu A, Marín F, Roldán V, et al. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels［J］. J Intern Med, 2007, 262(6):651-658.

［13］王燃燃，彭道泉，赵水平. 冠心病相关的炎症新指标OX40L［J］. 中华心血管病杂志， 2006， 34(12)：1110-1112.

［14］Kim H, Yang DH, Park Y, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome［J］. Circ J, 2006, 70(11):1379-1384.

［15］Cameron SJ, Sokoll LJ, Laterza OF, et al. A multi-marker approach for the prediction of adverse events in patients with acute coronary syndromes［J］. Clin Chim Acta, 2007, 376(1-2):168-173.

［16］Giansante C, Fiotti N, Di Chiara A, et al. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers［J］. J Cardiovasc Med, 2007, 8(8):602-607.

［17］Zhang SZ, Jin YP, Qin GM, et al. Association of platelet-monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients with non-st elevation acute coronary syndromes［J］. Clin Cardiol, 2007, 30(1):26-31.

［18］Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women［J］. N Engl J Med, 2004, 351(25):2599-2610.［19］Danesh J, Wheeler JG, Hirschfield GH, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease［J］. N Engl J Med, 2004, 350(14):1387-1397.

［20］Sukhija R, Fahdi I, Garza L, et al. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome［J］. Am J Cardiol, 2007, 99(7):879-884.

［21］Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy［J］. N Engl J Med, 2005, 352(1):20-28.

［22］孙英杰. 早期应用阿托伐他汀对急性冠脉综合征患者血浆IL-6和hs-CRP的影响［J］. 社区医学杂志， 2007， 5(3)：8-9.

［23］Macin SM, Perna ER, Farías EF, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study［J］. Am Heart J, 2005, 149(3):377-380.

［24］Gortney JS, Sanders RM. Impact of C-reactive protein on treatment of patients with cardiovascular disease［J］. Am J Health Syst Pharm, 2007, 64(19):2009-2016.

［25］赵卓，吴学思，韩志红，等. 不稳定心绞痛患者住院早期应用不同剂量普伐他汀的临床研究［J］. 中华心血管病杂志， 2005， 33(1)：54-57.

备注/Memo

备注/Memo:
收稿日期：2008-3-4.通讯作者：张荣林，副主任医师，主要从事冠心病诊治研究Email：zhangronglin2004@hotmail.com 作者简介：童廉琦，硕士生Email：terry-tong@hotmail.com
更新日期/Last Update: 2010-03-05